52 patents currently held
6 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jan 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
26
Ending by 2030
Jan 2027
Next term end
25
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Mar 2028 · High confidence
Also notable
Ends Nov 2031 · High confidence
Also notable
Ends Sep 2027 · High confidence
Modified FGF-21 Polypeptides and Their Uses
US 8,012,931
The most cited patent in this portfolio, cited by 149 later US patents, top 5% of utility patents granted in 2011 in our data. Protection runs to 2028.
Therapeutic Uses of Modified Relaxin Polypeptides
US 9,567,386
Cited by 36 later US patents, top 10% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2031.
Modified Human Plasma Polypeptide or FC Scaffolds and Their Uses
US 7,919,591
Cited by 86 later US patents, top 10% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 14, 2027The maintenance fee for Modified FGF-21 Polypeptides comprising non-naturally occurring amino acids. (US 9,079,971) comes due Jan 14, 2027. Unpaid by Jul 14, 2027, it lapses early.
- 1 fee due Feb 13, 2027The maintenance fee for Modified FGF-21 Polypeptides Comprising Non-Naturally Encoding Amino Acids and Their Uses (US 10,377,805) comes due Feb 13, 2027. Unpaid by Aug 13, 2027, it lapses early.
- 3 fees due Mar 1 to 15, 2027 · next Mar 1
- 2 fees due Apr 1 to 17, 2027 · next Apr 1
- 2 fees due Jun 26, 2027
Recent changes
- 4 terms have ended since Aug 16, 2026
What they patent
The 5 largest of its 25 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Modified FGF-21 Polypeptides and Their Uses | 7 in force | to Mar 2028 |
| Therapeutic Uses of Modified Relaxin Polypeptides | 6 in force | to Nov 2031 |
| Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides | 5 in force | to Mar 2028 |
| Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acid Linked Dolastatin Derivatives | 4 in force | to May 2033 |
| Anti-CD70 Antibody Drug Conjugates | 3 in force | to Jun 2033 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,175,083 | Novel Antigen-Binding Polypeptides and Their Uses In force · High confidence | In force | High confidence | |
| US 7,632,924 | Novel Antigen-Binding Polypeptides and Their Uses In force · High confidence | In force | High confidence | |
| US 7,632,823 | Compositions of Trna and Uses Thereof In force · High confidence | In force | High confidence | |
| US 7,919,591 | Modified Human Plasma Polypeptide or FC Scaffolds and Their Uses In force · High confidence | In force | High confidence | |
| US 9,868,972 | Hybrid Suppressor Trna for Vertebrate Cells In force · High confidence | In force | High confidence | |
| US 8,008,456 | Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides In force · High confidence | In force | High confidence | |
| US 8,906,676 | Modified Human Four Helical Bundle Polypeptides And Their Uses In force · High confidence | In force | High confidence | |
| US 8,809,511 | Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides In force · High confidence | In force | High confidence | |
| US 8,048,988 | Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides In force · High confidence | In force | High confidence | |
| US 8,791,231 | Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides In force · High confidence | In force | High confidence |
Also on record, not counted in the 52: 6 patents in force now held by others · 63 patents ended · 11 applications pending · 63 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.